
Sage Therapeutics, Inc. (NASDAQ:SAGE) came out with a quarterly loss of $2.13 per share versus the Zacks Consensus Estimate of a loss of $2.16. This compares to loss of $1.83 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 1.39%. A quarter ago, it was expected that this company would post a loss of $2.09 per share when it actually produced a loss of $2.07, delivering a surprise of 0.96%.